# Sun Pharmaceutical Industries Limited has received comprehensive clinical updates on two significant drug candidates in its pipeline.

*biotech · news · 2026-03-28 · scanx.trade*

## Key points

- Fibromun's Phase II trials in soft tissue sarcoma and glioblastoma did not meet primary endpoints.
- Survival benefit was observed in glioblastoma patients with limited alkylating agent exposure in GLIOSTAR trial.
- Nidlegy achieved complete pathological response in 52.60% of basal cell carcinoma patients in the Duncan study.
- Regulatory alignment with FDA enables Nidlegy’s continued US approval pathway pending ongoing Phase III results.
- New Phase III registrational trials for both Fibromun and Nidlegy are scheduled to initiate in 2026.

**Companies:** Sun Pharmaceutical Industries Limited
**Countries:** United States, Switzerland, Spain, Italy, France

[Read the full story on scanx.trade](https://scanx.trade/stock-market-news/companies/sun-pharmaceutical-provides-clinical-updates-on-fibromun-and-nidlegy-drug-trials/36213902)

---

Canonical: https://newsio.io/n/4cb797fe-9568-4ffc-bb90-678601412427/sun-pharmaceutical-industries-limited-has-received-comprehensive-clinical-update
Summarized by Newsio from scanx.trade. https://newsio.io/how-it-works